Published online 5 March 2008
Haematologica, Vol 93, Issue 4, 566-573 doi:10.3324/haematol.12364
Copyright © 2008 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Membre et al. - Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Membre, A.
Right arrow Articles by Regnault, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Membre, A.
Right arrow Articles by Regnault, V.

Platelet Disorders

The effect of platelet activation on the hypercoagulability induced by murine monoclonal antiphospholipid antibodies

Aurelie Membre1,2, Denis Wahl1,2,3, Veronique Latger-Cannard1,4, Jean-Pierre Max1,2, Patrick Lacolley2,5, Thomas Lecompte1,2,4, Veronique Regnault1,2

1 Inserm, U734, Nancy;
2 Nancy University, Nancy;
3 CHU Nancy, Vascular Medicine, Nancy;
4 CHU Nancy, Hematology Laboratory, Nancy and
5 Inserm, U684, Nancy, France

Correspondence: Veronique Regnault, Inserm U734-Nancy University-Nancy 1, Faculté de medecine, 9 avenue de la foret de Haye, 54500 Vandoeuvre-les-Nancy. France. E-mail:veronique.regnault{at}nancy.inserm.fr

Background: To identify the mechanisms of the hypercoagulability associated with antiphospholipid antibodies, we investigated antibody-mediated platelet activation and interference of antibodies with phospholipid-dependent reactions.

Design and Methods: We used two murine monoclonal antibodies, one against β2-glycoprotein I (7F6G), the other against prothrombin (28F4). Platelet activation was assessed by phospholipid-related platelet procoagulant activity. Endogenous thrombin potential without activated protein C (ETP0) and the activated protein C concentration that reduced the ETP0 by 50% (IC50-APC) were determined by calibrated automated thrombography.

Results: Both monoclonal antibodies mimicked the effect of IgG in 11 out of a series of 40 patients with antiphospholipid antibodies in thrombography. In the presence of their target, 7F6G and 28F4 at 200 µg/mL exhibited comparatively low and high binding to platelets and elicited low and high levels of procoagulant phospholipids on platelet surface, respectively. In platelet-poor plasma, these antibodies induced a 1.6 and >12-fold increase in IC50-APC, respectively, thus providing evidence for a procoagulant effect independent of platelet activation. The 84% decrease in ETP0 indicated that 28F4 also displayed an anticoagulant effect. In platelet-rich plasma, this anticoagulant effect was significantly less (23% decrease in ETP0), demonstrating that a high increase in procoagulant surfaces by platelet activation significantly antagonizes the anticoagulant effect of antiphospholipid antibodies. In both types of plasma, the inhibition of thrombin generation (reduced ETP0) was less than the inhibition of activated protein C activity (increased IC50-APC).

Conclusions: Our findings show that platelet activation reinforces the hypercoagulability induced by competition between antiphospholipid antibodies/target complexes and pro- and anticoagulant complexes for phospholipid surfaces.

Key words: antiphospholipid antibodies, thrombin generation, activated protein C resistance, platelet activation, murine monoclonal antibodies.




This article has been cited by other articles:


Home page
 BloodHome page
K. Devreese, K. Peerlinck, and M. F. Hoylaerts
Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants
Blood, January 28, 2010; 115(4): 870 - 878.
[Abstract] [Full Text] [PDF]